TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.
Type
Public
Founded
2001
Employees
48 (est)

Key People at TxCell

Christophe Sarlot

Christophe Sarlot

CFO
Francois Meyer

Francois Meyer

CEO

TxCell Locations

Valbonne, 06560, FR

TxCell Metrics

TxCell Summary

Founding Date

2001

Market capitalization

€35.7 M

Closing share price

€2.25

TxCell Market Value History

TxCell Company Life